Natural mucosal barriers and COVID-19 in children
BACKGROUND Coronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response to SARS cor...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2021-05-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.148694 |
id |
doaj-1c99c907b69c49c79f45f28cd81a5deb |
---|---|
record_format |
Article |
spelling |
doaj-1c99c907b69c49c79f45f28cd81a5deb2021-08-02T21:53:09ZengAmerican Society for Clinical investigationJCI Insight2379-37082021-05-0169Natural mucosal barriers and COVID-19 in childrenCarl A. PierceSharlene SyBenjamin GalenDoctor Y. GoldsteinErika OrnerMarla J. KellerKevan C. HeroldBetsy C. HeroldBACKGROUND Coronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response to SARS coronavirus 2 (SARS-CoV-2) protects against severe disease.METHODS Clinical outcomes, SARS-CoV-2 viral copies, and cellular gene expression were compared in nasopharyngeal swabs obtained at the time of presentation to the emergency department from 12 children and 27 adults using bulk RNA sequencing and quantitative reverse-transcription PCR. Total protein, cytokines, and anti–SARS-CoV-2 IgG and IgA were quantified in nasal fluid.RESULTS SARS-CoV-2 copies, angiotensin-converting enzyme 2, and TMPRSS2 gene expression were similar in children and adults, but children displayed higher expression of genes associated with IFN signaling, NLRP3 inflammasome, and other innate pathways. Higher levels of IFN-α2, IFN-γ, IP-10, IL-8, and IL-1β protein were detected in nasal fluid in children versus adults. Children also expressed higher levels of genes associated with immune cells, whereas expression of those associated with epithelial cells did not differ in children versus adults. Anti–SARS-CoV-2 IgA and IgG were detected at similar levels in nasal fluid from both groups. None of the children required supplemental oxygen, whereas 7 adults did (P = 0.03); 4 adults died.CONCLUSION These findings provide direct evidence of a more vigorous early mucosal immune response in children compared with adults and suggest that this contributes to favorable clinical outcomes.FUNDING NIH grants R01 AI134367, UL1 TR002556, T32 AI007501, T32GM007288, P30 AI124414; an Albert Einstein College of Medicine Dean’s COVID-19 Pilot Research Award; and the Eric J. Heyer, MD, PhD Translational Research Pilot Project Award.https://doi.org/10.1172/jci.insight.148694Infectious disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carl A. Pierce Sharlene Sy Benjamin Galen Doctor Y. Goldstein Erika Orner Marla J. Keller Kevan C. Herold Betsy C. Herold |
spellingShingle |
Carl A. Pierce Sharlene Sy Benjamin Galen Doctor Y. Goldstein Erika Orner Marla J. Keller Kevan C. Herold Betsy C. Herold Natural mucosal barriers and COVID-19 in children JCI Insight Infectious disease |
author_facet |
Carl A. Pierce Sharlene Sy Benjamin Galen Doctor Y. Goldstein Erika Orner Marla J. Keller Kevan C. Herold Betsy C. Herold |
author_sort |
Carl A. Pierce |
title |
Natural mucosal barriers and COVID-19 in children |
title_short |
Natural mucosal barriers and COVID-19 in children |
title_full |
Natural mucosal barriers and COVID-19 in children |
title_fullStr |
Natural mucosal barriers and COVID-19 in children |
title_full_unstemmed |
Natural mucosal barriers and COVID-19 in children |
title_sort |
natural mucosal barriers and covid-19 in children |
publisher |
American Society for Clinical investigation |
series |
JCI Insight |
issn |
2379-3708 |
publishDate |
2021-05-01 |
description |
BACKGROUND Coronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response to SARS coronavirus 2 (SARS-CoV-2) protects against severe disease.METHODS Clinical outcomes, SARS-CoV-2 viral copies, and cellular gene expression were compared in nasopharyngeal swabs obtained at the time of presentation to the emergency department from 12 children and 27 adults using bulk RNA sequencing and quantitative reverse-transcription PCR. Total protein, cytokines, and anti–SARS-CoV-2 IgG and IgA were quantified in nasal fluid.RESULTS SARS-CoV-2 copies, angiotensin-converting enzyme 2, and TMPRSS2 gene expression were similar in children and adults, but children displayed higher expression of genes associated with IFN signaling, NLRP3 inflammasome, and other innate pathways. Higher levels of IFN-α2, IFN-γ, IP-10, IL-8, and IL-1β protein were detected in nasal fluid in children versus adults. Children also expressed higher levels of genes associated with immune cells, whereas expression of those associated with epithelial cells did not differ in children versus adults. Anti–SARS-CoV-2 IgA and IgG were detected at similar levels in nasal fluid from both groups. None of the children required supplemental oxygen, whereas 7 adults did (P = 0.03); 4 adults died.CONCLUSION These findings provide direct evidence of a more vigorous early mucosal immune response in children compared with adults and suggest that this contributes to favorable clinical outcomes.FUNDING NIH grants R01 AI134367, UL1 TR002556, T32 AI007501, T32GM007288, P30 AI124414; an Albert Einstein College of Medicine Dean’s COVID-19 Pilot Research Award; and the Eric J. Heyer, MD, PhD Translational Research Pilot Project Award. |
topic |
Infectious disease |
url |
https://doi.org/10.1172/jci.insight.148694 |
work_keys_str_mv |
AT carlapierce naturalmucosalbarriersandcovid19inchildren AT sharlenesy naturalmucosalbarriersandcovid19inchildren AT benjamingalen naturalmucosalbarriersandcovid19inchildren AT doctorygoldstein naturalmucosalbarriersandcovid19inchildren AT erikaorner naturalmucosalbarriersandcovid19inchildren AT marlajkeller naturalmucosalbarriersandcovid19inchildren AT kevancherold naturalmucosalbarriersandcovid19inchildren AT betsycherold naturalmucosalbarriersandcovid19inchildren |
_version_ |
1721226595850518528 |